 hold pt lower forward ep estim still model comp
acceler rais pt new base valuat year analyst stephen anderson full summari
veru inc veru buy pt femal health busi back urology-focus pipelin advanc
beigen ltd bgne buy pt first nda accept china follow analyst jason mccarthi ph
corpor event call maxim salesperson inform
futur fit nutrit confer host vendetti nyc thur
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
inc cover klee ndr nyc ceo steve picket wed sept
inc cover klee ndr dalla brendan sullivan thur sept
agilysi inc cover klee ndr nyc ceo ramesh srinivasan cfo toni pritchett thur sept
agilysi inc cover klee ndr boston ceo ramesh srinivasan cfo toni pritchett fri sept
profir energi inc pfie cover jang ndr toronto ceo brenton hatch cfo ryan oviatt tue sept
lower forward ep estim still model
comp acceler rais pt new base
maintain hold rate chipotl mexican grill though rais
price target reflect shift base valuat
year
lower ep estim ep estim
ep estim
account lower comp estim higher labor
train cost follow recent food safety-rel closur ohio
still model gain tech off-premis initi think
join year-end menu daypart extens initi
expect lead sustain mid-to-high-single-digit comp
next two three quarter howev expect sg expens increas
conjunct chang
nevertheless expect addit margin expans
increas effici lower food cost
revis price target base ep estim
reluct increas alreadi premium multipl target
lower ep estim vs consensu
ep estim vs consensu
ep estim vs consensu reduc
comp estim follow food safety-rel incid close
restaur powel oh suburban columbu late juli restaur sinc
reopen sicken mani custom though none serious
address food safeti particularli safe storag handl temperatur
center diseas control cdc determin caus powel oh
incid expect manag increas labor train expens
margin translat ep impact annual basi begin
revis estim also includ higher sg expens tie
forthcom menu chang estim increment expens impact margin
per share annual basi nevertheless still
expect same-restaur sale remain posit thank easier y/i same-
restaur sale comparison solid push toward online/mobil sale adopt
help popular free guacamol promot quarter
valuat revis price target believ potenti upsid
initi propos ceo brian niccol balanc potenti
risk base yesterday close price share trade
ep estim ep estim come close shift
base valuat year believ cmg recoveri
stori price market given outlook posit
extend contend share trade near long-term averag
forward price-to-earnings base revis ep estim reduc
model yield price target price target also correspond
forward ev/ebitda ratio use base valuat year
cmg five-year pre-crisi averag ratio recommend investor seek
gain growth mexican limited-servic dine segment consid share
del tacobuy top sector pick
click full note
femal health busi back urology-focus
veru announc compani award south africa femal
condom tender total femal condom three year view
news signific posit continu help off-set
burn associ urolog pipelin see
signific valu upsid veru
south africa award veru ship femal condom
first year assum price base unit nation popul
fund unfpa price indic translat
per year addit revenu return revenu histor
conclus south africa one two largest consum brazil
femal condom compani also ship product countri
includ us re-emerg female/mal health busi
posit veru posit compani strateg term capit
need pipelin program partner opportun watch pipelin
three drug
femal condom one veru key commerci product nitril
femal condom prevent transmiss sexual transmit infect
hiv unwant pregnanc includ silicone-bas lubric allow free
movement intercours come multipl color scent version
offer new south africa tender present
femal condom fda-approv avail prescript reimburs
insur increas access importantli coverag also mandat
afford act compani distribut product non-profit commun
outreach program colleg univers gener
revenu fy sep came public sector usaid
unfpa brazil south africa femal condom sold south africa
tender award distribut biocor hospit suppli privat limit crystal
pier trade khusela pti ltd medproc cc qualiti medic suppli pti ltd
revalor condom pti ltd compani produc product kuala lumpur
manufactur plant capac unit annual
recal veru ship product countri total compani reli mostli
hand main custom two larg govern brazil south africa
usaid unfpa sale although financi specif award
south africa disclos estim unit tender come
total assum south africa tender price similar publish
price per unit femal nitril condom unit nation popul
fund unfpa price indic translat addit first year
anoth unit first year south africa tender bring
unit tender busi back histor base previous gener
revenu also watch potenti increas busi
us demand grow margin higher
model updat unit tender brazil new sale channel us
signific unit tender south africa three year
increas revenu estim
click full note
first nda accept china follow
beigen announc accept first new drug file nda
china drug administr cda btk inhibitor zanubrutinib
zanubrutinib also evalu global b-cell malign
includ waldenstrom macroglobulinemia wm global fulli enrol
wm zanubrutinib vs ibrutinib treatment chronic lymphocyt
leukemia cll pivot r/r follicular lymphoma combin
gazyva two pivot cll wm china r/r cll/small
lymphocyt lymphoma sll ibrutinib vs zanubrutinib next
like nr ibrutinib beigen look toward broad
approv zanubrutinib today approv ibrutinib combin
rituximab wm rare form non-hodgkin lymphoma first
chemotherapy-fre combin treatment wm posit
beigen potenti favor result global wm studi see
similar combin zanubrutinib futur
conclus beigen program progress rapidli one nda file
accept cda anoth file zanubrutinib us expect
wm well inhibitor tislelizumab r/r classic
hodgkin lymphoma r/r chl china
zanubrutinib mantl cell lymphoma mcl phase single-arm pivot studi
evalu zanubrutinib chines patient relaps refractori mcl
treat zanubrutinib dose mg oral twice daili independ review
respons data studi indic overal respons rate orr
includ patient achiev complet respons month median
follow-up median durat respons reach major
respond remain respons safeti profil consist previous
report clinic data zanubrutinib full result studi expect
zanubrutinib nda file data full result r/r mcl china full pivot
data wm studi well data on-going studi chronic lymphocyt
and/or china studi initi head-to-head vs ibrutinib r/r cll global
tislelizumab nda file relapsed/refractori classic hodgkin lymphoma r/r
chl china data updat pivot china r/r chl studi complet
enrol pivot urotheli carcinoma china initi addit pivot
sitravatinib studi initi combin tislelizumab
china studi initi combin tislelizumab solid tumor
us
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
